Search
for
Sort by
Research 571–600 of 1000+
- Hair growth promotion by Necrostatin-1s
- Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
- Endocrine treatment of benign prostatichypertrophy: Current concepts
- An overview of management of drug-induced hair and nail disorders
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Selection signatures for fiber production in commercial species: A review
- Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
- Integrated single-cell chromatin and transcriptomic analyses of peripheral immune cells in patients with alopecia areata
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Cutaneous Drug Eruptions Associated with the Use of Biologies and Cutaneous Drug Eruptions Mimicking Specific Skin Diseases
- Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle
- Diagnosis and treatments of hirsutism: where are we?
- Selective androgen receptor modulators: a critical appraisal
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- Management of Toxicities of Targeted Therapies
- Update on Frontal Fibrosing Alopecia
- Current and future pharmacotherapy for alopecia areata
- Diagnosis and Management of Infertility due to Anovulation
- LUPUS ERYTHEMATOSUS AND THE SKIN
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Alopecia Areata and Alopecia Areata Incognita
- 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
- Alopecia Areata
- Treatment guidelines in adult women
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study